Eikon Therapeutics has announced the initial closing of a $350.7 million Series D financing, led by existing investors. Since its founding in 2019, the company has privately raised over $1.1 billion.  “Eikon has made remarkable progress in advancing a pivotal-stage clinical pipeline and early-stage development programme powered by our single-molecule tracking technology and the deep […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!